Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC ...Middle East

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed...

Hence then, the article about akeso announced enrollment of first patient in phase 3 trial of cadonilimab for consolidation therapy after concurrent or sequential chemoradiotherapy in nsclc was published today ( Thursday 13/02/2025 - 04:31 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC )

Also on site :

• Thousands rally in Serbia as students continue fight against corruption
• Bank of England must plan for a financial crisis triggered by Aliens, says former policy expert
• 'SNL' Parodies 'Heated Rivalry' With Harry Potter Characters — And a Genius Cameo